WW International, Inc.'s SEC filings document the regulatory record for Weight Watchers' subscription-based weight-management and clinical businesses. Recent Forms 8-K furnish quarterly results, shareholder letters, Regulation FD disclosures about term-loan prepayment actions, and material governance events involving directors, board committees and interim executive officers.
The company's proxy materials cover annual-meeting voting matters, director elections, board independence, committee service and non-employee director compensation. Its filings also identify WW common stock, no par value, registered on the Nasdaq Stock Market and provide formal disclosure of capital-structure, compensation and corporate-governance matters.
WW International, Inc. Schedule 13G shows Fund 1 Investments, LLC beneficially owns 779,629 shares of Common Stock, representing 7.80% of the class.
The filing states these shares are held by private investment vehicles advised by Pleasant Lake Partners LLC, with Fund 1 Investments, LLC as managing member and Jonathan Lennon as managing member. The ownership percentage is calculated using 9,996,468 shares outstanding as of February 25, 2026.
WW International detailed the severance arrangements for former President and Chief Executive Officer Tara Comonte following her previously disclosed resignation effective March 31, 2026. On May 14, 2026, the company and Ms. Comonte entered into a Settlement Agreement and General Release and Waiver of Claims.
Under this agreement, Ms. Comonte will receive a cash settlement totaling $1,850,000, paid in two installments: $545,205.48 after the release becomes irrevocable and $1,304,794.52 on October 1, 2026. WW will also pay a gross amount of $150,000 directly to her legal counsel for attorneys’ fees and costs.
The agreement includes mutual releases of claims between the parties, a cooperation covenant benefiting the company, mutual non-disparagement, and mutual confidentiality regarding the negotiations and circumstances leading to the settlement. WW notes that the full Settlement Agreement will be filed as an exhibit to its Form 10-Q for the quarter ended June 30, 2026.
WW International reports that Cooper Creek Partners Management LLC, through John McCleary, beneficially owns 975,419 shares of common stock, representing 9.8% of the class. The filing states sole voting and sole dispositive power over these shares. The amendment is signed by John McCleary (CFO) on 05/15/2026.
WW INTERNATIONAL, INC. Schedule 13G/A amendment reports that Cooper Creek Partners Management LLC beneficially owns 9,986,920 shares of common stock, representing 9.8% of the class. The filing names John McCleary as the filing person and is signed on 05/15/2026.
The filing lists sole voting and sole dispositive power over the 9,986,920 shares. The statement includes certifications about the foreign regulatory scheme and that the holdings were not acquired to influence control.
WW INTERNATIONAL, INC. ownership disclosure: Jorey Chernett beneficially owned 507,356 shares of common stock as of May 14, 2026, representing 5.1% of the class. The percentage is calculated using 9,998,760 shares outstanding as of April 20, 2026, per the issuer's Form 10-Q.
WW INTERNATIONAL, INC. reported that Aristeia Capital, L.L.C. beneficially owns 748,478 shares of Common Stock, representing 7.49% of the class. The percentage is based on 9,996,468 shares outstanding as of April 20, 2026, per the issuer's 10-Q.
The filing (an amendment to a Schedule 13G) states Aristeia holds sole voting and dispositive power over the 748,478 shares.
Galloway Capital Partners, Galloway Capital LP and Bruce Galloway filed a Schedule 13D disclosing beneficial ownership of 841,700 shares of WW International common stock, representing 8.42% of the company’s outstanding shares as of April 20, 2026.
The position includes 378,700 shares of common stock and 463,000 shares underlying call options exercisable within 60 days. Galloway Capital Partners acquired 234,800 shares in open market purchases from March through May 2026 at an aggregate purchase price of about $12.26 per share, and the reporting persons bought call options for a total of $569,490.
The group states that the investment is for investment purposes but indicates it will continuously review its position and may buy more, hold, or sell shares. They also signal potential engagement with WW’s board and management on strategy, operations, governance and capital allocation, and have already sent a letter to management dated May 13, 2026.
WW International reported a challenging first quarter of 2026 as it continues operating post‑bankruptcy. Revenue was $168.3 million, down from $186.6 million a year earlier, with subscription revenue of $167.4 million. Higher marketing and overhead costs drove an operating loss of $30.4 million and a net loss of $52.0 million, or $5.20 per share.
Cash and cash equivalents were $120.9 million, but operations used $33.5 million of cash in the quarter. WW carries a $465.0 million New Term Loan Facility maturing in 2030 at an effective interest rate of about 10.5%, with a current portion of $26.8 million due. Goodwill totaled $200.0 million and the company flagged its Behavioral reporting unit and its $320.0 million trade name as at risk of future impairment, although no charges were recorded this quarter. WW also completed most actions under its 2025 restructuring plan and incurred additional restructuring charges while transitioning leadership after the CEO’s March 2026 resignation.
WW International reported first quarter 2026 results with revenue of $168.3 million and a net loss of $52.0 million. Subscription revenue was $167.4 million, including $128.5 million from Behavioral offerings and $38.8 million from faster‑growing Clinical offerings, where Clinical subscription revenue rose 31.8% year‑over‑year.
Total end‑of‑period subscribers were 2.659 million, with 2.463 million Behavioral and 197 thousand Clinical subscribers, as mix shifts toward higher‑value tiers lifted ARPU to $20.59, up 13% year‑over‑year. Adjusted EBITDA was a loss of $1.8 million, as marketing spending was front‑loaded to promote Med+ and GLP‑1 offerings, while Adjusted Gross Margin remained high at 73.6%.
The company ended the quarter with $120.9 million of cash and cash equivalents and long‑term debt of $438.6 million. It plans in Q2 to use $37 million of cash to retire $42 million of term‑loan principal, which is expected to cut annualized interest expense by approximately $4 million. Management reaffirmed full‑year 2026 guidance for revenue of $620–$635 million and Adjusted EBITDA of $105–$115 million, and continues to expect cash generation over the remaining quarters of 2026.